Ionis Q2 2026: TRYNGOLZA Launch Gains Traction, Pipeline Milestones on Track, Cash $2.1B
IONS sits 41% above its 52-week low of $40.03.
Summary
Ionis reported Q2 2026 earnings with $268M in revenue and a $115M net loss. The TRYNGOLZA sHTG launch is gaining traction, DAWNZERA sales jumped 63% QoQ, and 2026 guidance was reaffirmed. Key catalysts ahead include approval decisions for zilganersen and bepirovirsen, as well as pelacarsen Phase 3 data.
Key Events · Earnings and Guidance · IONS
-
Q2 2026 Financial Results
Total revenue reached $268M, with a net loss of $115M and cash of $2.1B. Excluding a one-time sapablursen upfront payment in Q2 2025, revenue grew 56%.
-
TRYNGOLZA sHTG Launch Momentum
Following its late-June sHTG approval, TRYNGOLZA generated $5M in Q2 net product sales. Full-year 2026 sales guidance remains $100-110M.
-
DAWNZERA Sales Growth
DAWNZERA net product sales hit $26M in Q2, a 63% increase from Q1 2026. Full-year guidance of $110-120M was reaffirmed.
-
Upcoming Regulatory Catalysts
The PDUFA date for zilganersen in Alexander disease is September 22, 2026; for bepirovirsen in chronic hepatitis B, it is October 26, 2026.
Analysis · IONS · Life Sciences
Ionis posted Q2 2026 revenue of $268M alongside a net loss of $115M, reflecting stepped-up commercialization spending for TRYNGOLZA and DAWNZERA. The early sHTG launch of TRYNGOLZA is building momentum, while DAWNZERA sales climbed 63% quarter-over-quarter. Management reaffirmed its 2026 guidance and pointed to upcoming catalysts: PDUFA dates for zilganersen and bepirovirsen, plus pelacarsen cardiovascular outcomes data. With $2.1B in cash, the company has ample runway to advance its wholly owned pipeline and remains on track for cashflow breakeven by 2028.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1609 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IONS was trading at $56.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1B. The 52-week trading range was $40.03 to $86.74. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.